According to the WHO 2024 Global Hepatitis Report, viral hepatitis is on the rise and remains the second leading infectious cause of death globally, claiming 1.3 million lives annually, equivalent to tuberculosis. Ten countries account for nearly two-thirds of the global burden of viral hepatitis B and C: China, India, Indonesia, Nigeria, Pakistan, Ethiopia, Bangladesh, Vietnam, The Philippines and the Russian Federation.
The APAC region is disproportionately affected, with 70 per cent of viral hepatitis deaths occurring here. Failure to act swiftly could lead to substantial economic losses, with projected costs of $558 billion for hepatitis B and $62 billion for hepatitis C due to illness and premature mortality, according to the Coalition for Global Hepatitis Elimination report.
WHO has set a goal to eliminate viral hepatitis by 2030, aiming for a 90 per cent reduction in incidence and a 65 per cent reduction in mortality from hepatitis B and C.
Progress so far
Most of the countries in the region have a national hepatitis elimination programme but progress remains somewhat unsatisfactory.
“Viral hepatitis has a devastating impact on South-East Asia and the Western Pacific regions, where an estimated 158 million people live with chronic hepatitis B and 16 million with chronic hepatitis C. Access to treatment for hepatitis B and C remains a challenge in many Asian countries due to cost and healthcare infrastructure limitations. Furthermore, vertical transmission (from mother to child) of hepatitis B is a major concern in the region. Such a heavy prevalence has a profound disruptive effect on society in the region. On top of causing a tragic loss of life, viral hepatitis poses a huge societal and financial burden and drives inequality,” said
Benedetta Nirta, Deputy Director and Fundraising Manager at The Hepatitis Fund, Geneva.
Denne historien er fra BioSpectrum Asia July 2024-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra BioSpectrum Asia July 2024-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
